**“Sick” MRI syndrome**

**M J Kushner**

At this time, MRI is a better indicator of tissue outcome rather than clinical destiny.

The report by Marx et al (this issue, pp572–575) joins the ever growing literature dealing with multiparametric MRI studies of tissue characteristics in stroke. Markers of ischaemic perturbations of cell homeostasis and perfusion, including changes in diffusion and perfusion weighted imaging (DWI and PWI), seem now to allow human stroke studies more analogous to animal models. Although debate rages, current optimism maintains that MRI delineates the three main tissue compartments in ischaemia. Conceptually these compartments are (a) irreversibly damaged tissue, (b) minimally disrupted tissue destined for eventual recovery, and (c) the “penumbra” or “borderzone” or “at-risk” region where outcome hangs in the balance between irrevocable damage and some degree of recovery, and which may be amenable to treatment.

Recent human data suggest that DWI and DWI-PWI mismatches strongly predict tissue outcome after ischaemia. Despite this progress in neuroimaging, clinical and clinicopathological MRI correlation has lagged behind. Reconciling recent MRI studies of stroke with each other is not straightforward, and it is also daunting to relate them to previous investigations of stroke using other reliable structural and haemometabolic techniques.

To date, human MRI studies have used many different paradigms, and this situation stands in contrast with standardised models found in the animal stroke literature. Variations in clinical criteria, imaging protocols, and myriad other factors introduce obvious confounding influences in these studies, and it should be assumed that lack of standardised approaches can only increase exposure to not so obvious bias.

Marx et al report a relatively high incidence of DWI changes following posterior circulation ischaemia where the clinical syndrome actually was transient or reversible. DWI alterations tended to be more prominent with longer lasting ischaemic symptoms yet were detected despite ultimate clinical recovery. This bears mention, indeed, for one would expect the observed DWI changes to bode ill when in actuality full recovery was the case. This represents a potential quandary: how should one reconcile a “sick” MRI with a healthy patient? A simple explanation may be that, at this time, MRI is a better indicator of tissue outcome rather than clinical destiny. If future reports invoke MRI as an indicator of clinical outcome, or as a marker of the impact of therapeutic intervention, then data will be needed across the full spectrum of stroke severity from fixed deficits to transient syndromes. Standardised study designs are needed so that the true utility of functional MRI is established in both natural history and interventional studies of stroke. Consensus on this score would be useful now, for the widespread availability of MRI, in contrast with other techniques such as PET or SPECT, suggests that this literature will continue to proliferate.

While this field remains in flux, clinical neurology should take note. At a minimum, these MRI markers of ischaemia must be regarded as new harbingers in the menagerie threatening haemometabolic risk, and attention must be paid. Their appearance should spur the clinician to redouble efforts to apply available medical and surgical treatments, whether they be acute, or preemptive and prophylactic, to address treatable haemorheological and haemodynamic abnormalities.

**REFERENCES**


**Author’s affiliations**

M J Kushner, Eastern Carolina University School of Medicine and the Wilson Neurology Center, Wilson, North Carolina, USA
value as a marker of risk if it can be shown to be both sensitive and prognostically useful. A fundamental problem that has thus far limited enthusiasm for the use of MRI in establishing prognosis (as opposed to establishing clinical-pathological correlations) has been the non-specificity of T2 hyperintensity—the most sensitive marker—on conventional MRI. T2 hyperintensity in white matter, for example, can arise from enlarged perivascular spaces, increased tissue fluid, inflammation, or gliosis.

In the paper by Yamauchi et al (this issue pp576–82) there are important new observations suggesting that conventional T2 weighted MRI may provide clinically useful information for risk stratification in an older stroke population. This paper follows a series of communications from several groups showing correlations between recognised risk factors such as hypertension and clinical syndromes such as cognitive impairment.

Yamauchi et al followed prospectively 89 patients who either had symptomatic lacunar infarcts or who were neurologically normal and presented for other reasons. Subjects with large vessel disease were specifically excluded. White matter lesions were considered separately, only the extent of white matter lesion changes was an independent predictor of later stroke. Over the follow up period none of the patients showed regression of white matter lesions, suggesting irreversible pathology. Extending the association of white matter lesion extent with stroke risk found in the cross sectional studies, patients showing increases in white matter lesion load during the period of observation had a greater risk of future stroke. The risk of stroke increases substantially after an initial cerebrovascular event. However, it has been less clear whether white matter changes can be interpreted as “silent strokes” that similarly contribute to risk. This study persuasively supports the notion that the extent of white matter lesion changes is an independent predictor and may provide prognostic information. Further work is needed to confirm these findings. Potential areas for such further work include the application of objective criteria for evaluation, the use of whole brain imaging, and thinner slices to improve the definition of changes. Nonetheless, Yamauchi et al offer the gratifying prospect of better targeting of aggressive management, although clearly a substantial therapeutic challenge remains—a disappointing observation in their study was that the severe white matter lesion group continued to have a higher risk of stroke despite apparently appropriate conventional management of vascular factors during the follow up period. Greater future effort might be directed towards developing therapeutic strategies directed at high risk populations, defined jointly by clinical and imaging measures.

J Neurol Neurosurg Psychiatry 2002;72:564–565

Author’s affiliations
P M Matthews, Centre for Functional MRI of the Brain, John Radcliffe Hospital, Headington, Oxford OX3 9DU, UK; paul@fmrib.ox.ac.uk

REFERENCES

Dementia

Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer’s disease

C Ballard, J O’Brien, M Tovee

New approach to assessment of patients with dementia with Lewy bodies is clinically useful in differentiating them from patients with Alzheimer’s disease

Accurate and early clinical diagnosis of dementia with Lewy bodies (DLB) is essential for optimal management so that pitfalls such as severe neuropsychiatric sensitivity 1 can be avoided, a trial of cholinesterase treatment can be instigated, 2 and parkinsonian symptoms 3 can be appropriately treated, weighing up the balance of psychiatric and motor symptoms and fall risk. In practice it has often been difficult to differentiate DLB from other forms of dementia, particularly Alzheimer’s disease. Several previous studies have suggested that DLB and Alzheimer’s disease can be differentiated on the basis of visual and visuospatial tasks. 4 The tasks most easily applicable to initial diagnosis are drawing tests (such as the clock drawing). However, this approach ignores what is one of the more striking features of DLB: fluctuating cognition. Operationalised criteria for the clinical diagnosis of DLB (which do consider a broad range of symptoms) have achieved high levels of specificity ( 90% ); in many studies sensitivity has been as low as 50%. 5 Probably the major obstacle to accurate diagnosis has been the difficulty of identifying fluctuating cognition; for example, two inter-rater reliability studies have indicated that agreement
between expert clinicians is barely better than chance.¹¹

A body of work focusing on these issues has validated two clinical rating scales¹¹ and indicated that fluctuation of reaction time on attentional tasks¹¹ and variability in spectral frequency assessed by electroencephalography¹¹ can also be useful methods for identifying and quantifying fluctuating cognition, which seems to be closely linked to impairments of consciousness.

In the paper by Doubleday et al.¹¹ (this issue, pp602–607) tackles these issues in an innovative way. The authors developed a standardised qualitative instrument based on observations of the patient during the course of the testing session. Information is obtained regarding a number of helpful domains including general inattention, distraction, and intrusions. Of particular interest, general inattention, distractibility, and environmentally cued intrusions were all significantly more common in DLB than in Alzheimer's disease, the latter occurring only in patients with DLB. In addition to the potential diagnostic value, this may be helpful in facilitating an understanding of the types of processing errors that are prominent in these patients. Perseveration and mental set shifting were also significantly more impaired in patients with DLB and they were more likely to confabulate. This assessment method has been used as part of the standard diagnostic protocol that has achieved a high level of accuracy in 200 people with dementia at postmortem examination, although it is unclear how many of these people had neuropathologically confirmed DLB. Further work is needed to examine the inter-rater reliability and concurrent validity of the instrument, and comparisons between DLB and other dementias would also be helpful. In particular, patients with vascular dementia often experience some degree of fluctuating cognition and may be more prone to difficulties with set shifting and perseveration. Diagnostic discrimination between DLB and vascular dementia can be difficult and it would be useful to know whether the proposed assessment method can also contribute to this diagnostic issue. Therefore, although the method needs to be developed a little more, the work presents a new and useful approach that is very clinically applicable and that may be of considerable value in the assessment of patients with DLB.

J Neurol Neurosurg Psychiatry 2002;72:565–566

Authors’ affiliations
C Ballard, J O’Brien, M Tovee, Institute for Ageing and Health, Wolfson Research Centre, Newcastle upon Tyne, UK
Correspondence to: Professor C Ballard, Wolfson Research Centre, Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, UK; c.g.ballard@newcastle.ac.uk

References